| 000 | 01405 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250516115041.0 | ||
| 264 | 0 | _c20130308 | |
| 008 | 201303s 0 0 eng d | ||
| 022 | _a2159-8290 | ||
| 024 | 7 |
_a10.1158/2159-8290.CD-12-0387 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlakely, Collin M | |
| 245 | 0 | 0 |
_aResiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. _h[electronic resource] |
| 260 |
_bCancer discovery _cOct 2012 |
||
| 300 |
_a872-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aClass I Phosphatidylinositol 3-Kinases |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aQuinazolines _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xbiosynthesis |
| 700 | 1 | _aBivona, Trever G | |
| 773 | 0 |
_tCancer discovery _gvol. 2 _gno. 10 _gp. 872-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/2159-8290.CD-12-0387 _zAvailable from publisher's website |
| 999 |
_c22188064 _d22188064 |
||